Registration to the career fair
OPKO Biologics (formerly Prolor Biotech), a subsidiary of OPKO Health Inc., is a clinical stage company developing next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs, utilizing CTP and reversible PEGylation technologies. The CTP technology involves fusing one or more copies of a naturally occurring glycosylated peptide by rDNA technology to the protein chain ends. When attached to a therapeutic protein, CTP significantly extends its longevity in the body.
OPKO Biologics’ second technology is reversible PEGylation, a synthetic chemistry-based platform for enhancing the half-life of therapeutic peptides and small molecules. Using a hydrolysable linker bypasses the disadvantages of using a standard PEGylated molecule, i.e. the potential for steric hindrance that limits its function, and the limited ability to cross cellular membranes or the blood-brain barrier.
16 Ashlegan St. Kiryat Gat